Similarly, almost all studies testing the effects of iron in CKD patients have been exclusively focused on the role of iron supplementation on anemia management by evaluating as primary outcomes either Hb increase, the achievement of Hb target, or ESA dose reduction [34]. This evidence concerns the gene GSTM1 and chronic kidney disease.